Patient Safety Guide for Erdafitinib and Enfortumab Vedotin: What to Look for and What to Report to Your Healthcare Team

Download this PDF patient safety guide for a quick resource on signs and symptoms of specific AEs patients should look for while they are receiving erdafitinib or enfortumab vedotin.
person default
Kinjal Patel, PharmD, BCOP
Susan Roethke, CRNP, MSN, AOCN, ANP-BC
Format: Adobe Acrobat (.pdf)
File Size: 80 KB
Released: January 6, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Astellas and Seattle Genetics, Inc.

Related Content

Slides on checkpoint inhibitors in first-line, second-line, and maintenance settings for urothelial carcinoma, from Clinical Care Options (CCO)

Cora N. Sternberg, MD, FACP Released: February 26, 2021

Slides on erdafitinib, enfortumab vedotin, and sacituzumab govitecan for progressive urothelial carcinoma, from Clinical Care Options (CCO)

Petros Grivas, MD, PhD Released: February 26, 2021

Downloadable slideset with key highlight data from the virtual 2021 ASCO GU Cancers Symposium provided by Clinical Care Options (CCO)

Robert Motzer, MD Daniel P. Petrylak, MD Released: February 25, 2021

Downloadable slideset from Clinical Care Options (CCO) exploring current and emerging first-line treatment options for patients with metastatic bladder cancer.

Matthew Galsky, MD Released: February 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue